Arca
Skip to content

Asthma

Drug research and approvals for asthma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 376 studies of asthma are recruiting on ClinicalTrials.gov, Health Canada has authorized 154 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 20 authorised medicines for it.

  • Recruiting worldwide: 376
  • Trials authorized in Canada: 154
  • FDA orphan approvals: 0
  • EU medicines: 20

Recruiting Now

Newest start dates first, of 376 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 154; search them all in Canada trials
Aug 28, 2026A phase 2b, multicenter, randomized, double-blind, placebo controlled, dose-ranging trial to evaluate the efficacy and safety of jnj-95597528 for the treatment…JNJ-95597528Johnson & JohnsonPending
Jul 27, 2026A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of add-on lunsekimig in adolescents and adults with…LUNSEKIMIG (SAR443765)SANOFI-AVENTIS CANADA INCPending
May 20, 2026The modify study: a phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on…DEPEMOKIMAB (GSK3511294)GSKOngoing
Mar 24, 2026Evaluating the impact of single dose tiotropium on allergen-induced early asthmatic responseTIOTROPIUMUNIVERSITY OF SASKATCHEWANPending
Nov 25, 2025A multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of…DUPIXENTUNIVERSITÉ DE SHERBROOKEOngoing
Nov 14, 2025A randomized, double-blind, placebo-controlled phase 2a study of aro-rage inhalation solution to assess efficacy on small airway dysfunction in…ADS-015ARROWHEAD PHARMACEUTICALS, INC.Ongoing
Oct 8, 2025A phase 2, multicenter, randomized, double-blind, 52-week study, to investigate the efficacy and safety of brenipatide compared with placebo for the treatment…BRENIPATIDE (LY3537031)Eli LillyOngoing
Oct 3, 2025Paxt: pulmonary imaging of mild asthma using 129-xenon mri and tc-99-labeled-carbon-imaging (tc99cimaging)HYPERPOLARIZED XENON-129ROBARTS RESEARCH INSTITUTEOngoing
Sep 19, 2025Reverse lung airway and vascular remodeling in asthma remission (renorm)HYPERPOLARIZED XENON-129ROBARTS RESEARCH INSTITUTE, WESTERN UNIVERSITYOngoing
Sep 3, 2025Understanding the role of airway mucus occlusions in canadians with asthma, copd and chronic cough (canmuc)HYPERPOLARIZED XENON-129MCMASTER UNIVERSITYPending

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Sep 21, 1989TroleandomycinTreatment of severe steroid-requiring asthma.Szefler, Stanley M. M.D.Designated

Medicines Authorised in the EU

Newest first; 15 of 20
Feb 12, 2026ExdensurdepemokimabGlaxoSmithKline Trading Services LimitedEMA ↗
May 16, 2024Omlycloomalizumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Sep 19, 2022TezspiretezepelumabAstraZeneca ABEMA ↗
Jan 6, 2022Riltrava Aerosphereformoterol fumarate dihydrate;glycopyrronium;budesonideAstraZeneca ABEMA ↗
Mar 26, 2021Seffalair Spiromaxsalmeterol;fluticasone propionateTeva B.V.EMA ↗
Dec 9, 2020Trixeo Aerosphereformoterol;glycopyrronium bromide;budesonideAstraZeneca ABEMA ↗
Jul 3, 2020Enerzair Breezhalerindacaterol;glycopyrronium bromide;mometasoneNovartis Europharm LimitedEMA ↗
Jul 3, 2020Zimbus Breezhalerindacaterol;glycopyrronium;mometasone furoateNovartis Europharm LimitedEMA ↗
May 30, 2020Atectura Breezhalerindacaterol;mometasoneNovartis Europharm LimitedEMA ↗
May 30, 2020Bemrist Breezhalerindacaterol;mometasoneNovartis Europharm LimitedEMA ↗
Apr 3, 2020GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.)budesonide;formoterol fumarate dihydrateTeva Pharma B.V.EMA ↗
Jan 8, 2018FasenrabenralizumabAstraZeneca ABEMA ↗
Jul 17, 2017Trimbowbeclometasone;formoterol;glycopyrronium bromideChiesi Farmaceutici S.p.A.EMA ↗
Aug 15, 2016CinqaeroreslizumabTeva B.V.EMA ↗
Dec 1, 2015NucalamepolizumabGlaxoSmithKline Trading Services LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.